Targeted therapy in the form of selective tyrosine kinase inhibitors (TKI) has transformed the
approach to management of chronic myeloid leukemia (CML) and dramatically improved …

Although only 5000 new cases of chronic myeloid leukemia (CML) were seen in the United
States in 2009, this neoplasm continues to make scientific headlines year-after-year …

Imatinib is a molecularly targeted therapy that inhibits the oncogenic fusion protein BCR-
ABL, the tyrosine kinase involved in the pathogenesis of chronic myelogenous leukemia …

The development of tyrosine kinase inhibitors (TKIs) has led to extended lifespans for many
patients with chronic myelogenous leukemia (CML). However, 20% to 30% of patients fail to …

Mechanisms of resistance to the tyrosine kinase inhibitor (TKI) imatinib had been modeled in
vitro even prior to the first reports of clinical resistance in patients with chronic myeloid …

The advent of the Bcr-Abl selective tyrosine kinase inhibitor imatinib mesylate (Glivec,
Gleevec, Novartis, East Hanover, NJ) has substantially changed the treatment landscape for …

Purpose: Review the state-of-art knowledge of the biology and therapy of chronic
myelogenous leukemia (CML). Experimental Design: A review of the literature was …

Given its relative rarity, it may at first seem surprising that chronic myeloid leukemia (CML)
has garnered so much attention over the last decade. Yet, the advances in molecular …

Selective inhibition of the BCR-ABL tyrosine kinase by imatinib has substantially changed
the therapy of chronic myelogenous leukemia (CML). Despite high rates of hematologic and …

Since its approval in 2001 for frontline management of chronic myelogenous leukemia
(CML), imatinib has proven to be very effective in achieving high remission rates and …